InflaRx N.V. announced its financial results for the full year ended December 31, 2024, reporting revenues from GOHIBIC product sales of €0.2 million, an increase of €0.1 million compared to 2023. The company incurred a net loss of €46.1 million, or €0.78 per ordinary share, in 2024, compared to €42.7 million, or €0.78 per ordinary share, in 2023.
Research and development expenses decreased by €5.7 million to €35.4 million in 2024, primarily due to lower third-party costs from manufacturing development and clinical trials. Marketing and sales expenses increased by €2.8 million, reflecting the first full year of commercial efforts for GOHIBIC in the United States. Net cash used in operating activities increased to €48.6 million in 2024 from €37.8 million in 2023, mainly due to lower income from government grants.
As of December 31, 2024, InflaRx's total available funds amounted to approximately €55.2 million. This financial position was bolstered by a public offering in February 2025, which raised gross proceeds of €28.7 million ($30.0 million), extending the company's cash runway into 2027.
Operationally, the European Commission granted marketing authorization for GOHIBIC (vilobelimab) in January 2025 for SARS-CoV-2-induced ARDS. The company also achieved the 30-patient recruitment milestone in November 2024 for its Phase 3 vilobelimab trial in pyoderma gangrenosum, with an interim analysis expected by the end of May 2025. Topline Phase 2a data for INF904 in chronic spontaneous urticaria and hidradenitis suppurativa are anticipated in summer 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.